Novo Nordisk targets -2% to +2% 2026 sales growth at CER while expecting DKK 60B to DKK 70B free cash flow

Novo Nordisk Q3 2026: raised guidance, GLP-1 growth, Wegovy pill momentum, and 2027 risks.